Algunos de estos medicamentos han demostrado beneficios cardiovasculares especficos: liraglutida, semaglutida inyectable y dulaglutida reducen eventos cardiovasculares en pacientes con diabetes tipo 2 y enfermedad cardiovascular
That does not make them ineffective
We will help you figure out what is driving the change and what your options are.
4 Mao X, Zhang X, Henry L, et al
After the knockout of the GLP-1R gene, in transgenic mice expressing human GLP-1R in pancreatic islets and pancreatic ductal cells restored cAMP and serine threonine kinase (Akt) phosphorylation levels in isolated islets, increased GLP-1-stimulated insulin secretion and GLP-1R-dependent -cell proliferation, and promoted transgenic mice for glucose regulation in response to feeding (Lamont et al., 2012)
These enforcement actions run parallel to mounting regulatory pressure